论文部分内容阅读
目的分析并评价采用阿魏酸钠治疗早期糖尿病肾病的临床治疗效果。方法将我院自2009年10月至2011年4月期间收治的122例早期糖尿病肾病患者随机分为两组各61例,对照组与治疗组分别采用复方丹参及阿魏酸钠静脉滴注,对比分析治疗前后患者的尿微量白蛋白/肌酐(MA/Cr)、β2微球蛋白(β2-MG)以及血肌酐(SCr)等的变化情况。结果观察组与对照组治疗后MA/Cr、β2-MG以及SCr均明显低于治疗前,差异显著(P均<0.01),具有统计学意义;治疗后对照组MA/Cr、β2-MG以及SCr明显高于治疗组,表明治疗组疗效要优于对照组疗效,差异显著(P均<0.01),具有统计学意义。在整个治疗过程中,两组患者均未见不良反应发生,患者血常规、肝功能及肾功能同治疗前相比均未见显著差异(P>0.05),不具有统计学意义。结论阿魏酸钠在治疗早期糖尿病肾病方面疗效理想,而且未见不良反应,值得临床上广泛应用。
Objective To analyze and evaluate the clinical efficacy of sodium ferulate in the treatment of early diabetic nephropathy. Methods A total of 122 patients with early diabetic nephropathy admitted in our hospital from October 2009 to April 2011 were randomly divided into two groups of 61 cases each. The control group and the treatment group were treated with compound Danshen and sodium ferulate, The changes of urinary albumin / creatinine (MA / Cr), β2-microglobulin (β2-MG) and serum creatinine (SCr) in patients before and after treatment were analyzed. Results The levels of MA / Cr, β2-MG and SCr in observation group and control group after treatment were significantly lower than those before treatment (all P <0.01), with statistical significance. After treatment, MA / Cr, SCr was significantly higher than the treatment group, indicating that the efficacy of the treatment group is better than the control group, the difference was significant (P all <0.01), with statistical significance. During the whole course of treatment, no adverse reactions occurred in both groups. There was no significant difference in blood routine, liver function and renal function between the two groups (P> 0.05), which was not statistically significant. Conclusion Sodium ferulate in the treatment of early diabetic nephropathy with good curative effect, and no adverse reactions, it is widely used in clinical.